242 related articles for article (PubMed ID: 11714734)
1. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
Takemoto M; Node K; Nakagami H; Liao Y; Grimm M; Takemoto Y; Kitakaze M; Liao JK
J Clin Invest; 2001 Nov; 108(10):1429-37. PubMed ID: 11714734
[TBL] [Abstract][Full Text] [Related]
2. Impact of HMG CoA reductase inhibition on small GTPases in the heart.
Laufs U; Kilter H; Konkol C; Wassmann S; Böhm M; Nickenig G
Cardiovasc Res; 2002 Mar; 53(4):911-20. PubMed ID: 11922901
[TBL] [Abstract][Full Text] [Related]
3. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy.
Nakagami H; Takemoto M; Liao JK
J Mol Cell Cardiol; 2003 Jul; 35(7):851-9. PubMed ID: 12818576
[TBL] [Abstract][Full Text] [Related]
4. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms.
Nakagami H; Jensen KS; Liao JK
Ann Med; 2003; 35(6):398-403. PubMed ID: 14572163
[TBL] [Abstract][Full Text] [Related]
5. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy.
Custodis F; Eberl M; Kilter H; Böhm M; Laufs U
Cardiovasc Res; 2006 Jul; 71(2):342-51. PubMed ID: 16698001
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Rugale C; Delbosc S; Mimran A; Jover B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):293-8. PubMed ID: 17878758
[TBL] [Abstract][Full Text] [Related]
8. Role of calcineurin in angiotensin II-induced cardiac myocyte hypertrophy of rats.
Fu M; Zhang J; Xu S; Pang Y; Liu N; Tang C
Chin Med Sci J; 2001 Mar; 16(1):1-4. PubMed ID: 12899339
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin inhibits angiotensin II-induced cardiac cell hypertrophy: role of Homer 1a.
Guo WG; Su FF; Yuan LJ; Yang GD; Shi XQ; Li RY; Shu Q; Liu XT; Lu ZF; Zheng QS
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):40-5. PubMed ID: 19515066
[TBL] [Abstract][Full Text] [Related]
10. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
[TBL] [Abstract][Full Text] [Related]
11. Effects of simvastatin on activities of endogenous antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy.
Luo JD; Zhang WW; Zhang GP; Zhong BH; Ou HJ
Acta Pharmacol Sin; 2002 Feb; 23(2):124-8. PubMed ID: 11866871
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
Luo JD; Xie F; Zhang WW; Ma XD; Guan JX; Chen X
Br J Pharmacol; 2001 Jan; 132(1):159-64. PubMed ID: 11156573
[TBL] [Abstract][Full Text] [Related]
13. Statins and the myocardium.
Mital S; Liao JK
Semin Vasc Med; 2004 Nov; 4(4):377-84. PubMed ID: 15861318
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA.
Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG
Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071
[TBL] [Abstract][Full Text] [Related]
15. [Simvastatin inhibits hypertension-induced cardiac hypertrophy in rats through activation of heme oxygenase-1/carbon monoxide pathway].
Yao HM; Wu XS; Zhang J; Geng B; Tang CS
Sheng Li Xue Bao; 2006 Apr; 58(2):116-23. PubMed ID: 16628357
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin attenuates hypertrophy of neonatal rat cardiac myocytes induced by angiotensin-II in vitro.
Wen Y; Zhang XJ; Ma YX; Xu XJ; Hong LF; Lu ZH
Scand J Clin Lab Invest; 2009; 69(4):518-25. PubMed ID: 19347742
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway.
Liu J; Shen Q; Wu Y
Life Sci; 2008 May; 82(19-20):991-6. PubMed ID: 18400235
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid B protects cardiomyocytes from angiotensin II-induced hypertrophy via inhibition of PARP-1.
Liu M; Ye J; Gao S; Fang W; Li H; Geng B; Zou J; Chen X; Chen S; Zhang L; Yue Z; Ma Y; Gao H; Li Z; Liu P
Biochem Biophys Res Commun; 2014 Feb; 444(3):346-53. PubMed ID: 24462865
[TBL] [Abstract][Full Text] [Related]
19. [Simvastatin attenuated cardiac hypertrophy via inhibiting JAK-STAT pathways].
Wu Y; Liu J
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Aug; 36(8):738-43. PubMed ID: 19100119
[TBL] [Abstract][Full Text] [Related]
20. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Danesh FR; Sadeghi MM; Amro N; Philips C; Zeng L; Lin S; Sahai A; Kanwar YS
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8301-5. PubMed ID: 12048257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
